| Name | Title | Contact Details |
|---|
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Arizona Benefit Plans is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CELLEX BIOSCIENCES is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.